Angion Biomedica Corp. – NASDAQ:ANGN

Add to watchlist

Market closed

Open in about 10 hours

+26.67%

month

+43.92%

quarter

-28.03%

year

Market Cap	30.11M
Enterprise value	N/A

P/E	-0.37
EV/Sales	-13.93
EV/EBITDA	0.86
Price/Sales	6.39
Price/Book	0.33
PEG ratio	-0.01
EPS	-4.24

Revenue	N/A
EBITDA	-23.75M
Income	-34.19M
Revenue Q/Q	N/A
Revenue Y/Y	-100%

Profit margin	-1686.53%
Oper. margin	-1463.62%
Gross margin	0%
EBIT margin	-1463.62%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Angion Biomedica Corp. (NASDAQ:ANGN): Profit margin
Dec 2022	0	-11.51M
Mar 2023	0	-4.46M
Jun 2023	0	-7.55M
Sep 2023	0	-10.65M

Angion Biomedica Corp. (NASDAQ:ANGN): Earnings per share (EPS)
2023-08-21	0.57	-2.43763

Angion Biomedica Corp. (NASDAQ:ANGN): Debt to assets
Dec 2022	52790000	9.01M	17.08%
Mar 2023	41767000	2.10M	5.03%
Jun 2023	37619000	14.06M	37.38%
Sep 2023	30987000	17.70M	57.12%

Angion Biomedica Corp. (NASDAQ:ANGN): Cash Flow
Jun 2022	-9.90M	0	-14K
Sep 2022	-8.40M	0	-17K
Dec 2022	-4.42M	0	-15K
Mar 2023	-8.07M	-10M	-3.26M

Angion Biomedica Corp. alternative data

Angion Biomedica Corp.
Employees

Angion Biomedica Corp. (NASDAQ:ANGN): Employee count
Aug 2023	3
Sep 2023	3
Oct 2023	3
Nov 2023	3
Dec 2023	3
Jan 2024	3
Feb 2024	3
Mar 2024	3
Apr 2024	3
May 2024	3
Jun 2024	3
Jul 2024	3

Angion Biomedica Corp.
Hedge Funds Holdings Q1 2023

4.18% -12.13%

of ANGN is owned by hedge funds

17 -13

hedge funds hold ANGN stock

1.25M -3.65M

shares is hold by hedge funds

ANGN hedge funds holdings changes

Angion Biomedica Corp.
Insider Trading

Angion Biomedica Corp. (NASDAQ:ANGN): Insider trades (number of shares)
Period	Buy	Sel
Dec 2023	1213000	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	22 Dec 2023	CHUDNOVSKY YEKATERINA director, 10 percent owner: director, 10 percent owner:	Common Stock	1,213,000	$5.81	$7,047,530
Purchase	25 May 2022	VENKATESAN JAY director, officer: director, officer:	Common Stock	11,313	$1.25	$14,107
Purchase	24 May 2022	VENKATESAN JAY director, officer: President and Chief Exec.. director, officer: President an..	Common Stock	32,200	$1.24	$39,928
Purchase	20 May 2022	NISSENSON ALLEN director director	Common Stock	2,037	$1.18	$2,404
Purchase	20 May 2022	VENKATESAN JAY director, officer: President and Chief Exec.. director, officer: President an..	Common Stock	50,000	$1.23	$61,500
Purchase	19 May 2022	NISSENSON ALLEN director director	Common Stock	7,346	$1.16	$8,521
Purchase	28 Dec 2021	VENKATESAN JAY director, officer: President and Chief Exec.. director, officer: President an..	Common Stock	210,337	$2.66	$559,917
Purchase	27 Dec 2021	VENKATESAN JAY director, officer: President and Chief Exec.. director, officer: President an..	Common Stock	66,907	$2.55	$170,546
Purchase	20 Dec 2021	VENKATESAN JAY director, officer: President and Chief Exec.. director, officer: President an..	Common Stock	3,527	$2.55	$8,976
Sale	20 Dec 2021	NEYLAN JOHN F. officer: Senior Vice President and Chief Me.. officer: Senior Vice President ..	Common Stock	358	$2.62	$938

ANGN insider trading transactions

Angion Biomedica Corp.
Executives

Insider	Age	Compensation
Ms. Jennifer J. Rhodes J.D. (1970) Senior Vice President, Gen. Counsel, Chief Compliance Officer & Corporation Sec.	55	$500,000
Dr. Jay R. Venkatesan M.B.A., M.D., Ph.D. (1972) Pres, Chief Executive Officer & Director	53	$390,000
Mr. Gregory S. Curhan (1962) Interim Chief Financial Officer	63	$359,010

Angion Biomedica Corp.
Latest News

Wednesday, 18 January 2023
14:18	Angion (ANGN) Down on Merger Agreement With Private Biotech	Zacks Investment Research
Wednesday, 16 November 2022
09:02	New Strong Buy Stocks for November 16th	Zacks Investment Research
Tuesday, 25 October 2022
09:02	New Strong Buy Stocks for October 25th	Zacks Investment Research
Thursday, 30 June 2022
06:11	Angion Biomedica Pulls The Plug On Another Kidney Disease Trial - Read Why	Benzinga
Wednesday, 1 June 2022
07:00	What to Know About Buying Penny Stocks on June 1st	PennyStocks
Wednesday, 11 May 2022
09:02	5 Biotech Stocks Set to Outpace Q1 Earnings Estimates	Zacks Investment Research
Monday, 13 December 2021
13:50	Angion (ANGN) Kidney Drug Misses Third Study Goal in 2021	Zacks Investment Research
Monday, 18 October 2021
16:05	Angion to Present Multiple Posters at Kidney Week 2021	GlobeNewsWire
Wednesday, 8 September 2021
00:05	Angion Hosting Research & Development Day on ANG-3070 for the Treatment of Lung and Kidney Fibrosis	GlobeNewsWire
Thursday, 2 September 2021
00:20	Angion to Participate in Upcoming September Investment Conferences	GlobeNewsWire

Frequently Asked Questions (FAQ)

When is Angion Biomedica Corp.'s next earnings date?

Unfortunately, Angion Biomedica Corp.'s (ANGN) next earnings date is currently unknown.
Does Angion Biomedica Corp. pay dividends?

No, Angion Biomedica Corp. does not pay dividends.
How much money does Angion Biomedica Corp. make?

Angion Biomedica Corp. has a market capitalization of 30.11M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 91.87% to 2.3M US dollars. Angion Biomedica Corp. made a loss 55.7M US dollars in net income (profit) last year or -$2.44 on an earnings per share basis.
What is Angion Biomedica Corp.'s stock symbol?

Angion Biomedica Corp. is traded on the NASDAQ under the ticker symbol "ANGN".
What is Angion Biomedica Corp.'s primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Angion Biomedica Corp.?

Shares of Angion Biomedica Corp. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Angion Biomedica Corp.'s key executives?
Angion Biomedica Corp.'s management team includes the following people:
- Ms. Jennifer J. Rhodes J.D. Senior Vice President, Gen. Counsel, Chief Compliance Officer & Corporation Sec.(age: 55, pay: $500,000)
- Dr. Jay R. Venkatesan M.B.A., M.D., Ph.D. Pres, Chief Executive Officer & Director(age: 53, pay: $390,000)
- Mr. Gregory S. Curhan Interim Chief Financial Officer(age: 63, pay: $359,010)
How many employees does Angion Biomedica Corp. have?

As Jul 2024, Angion Biomedica Corp. employs 3 workers.
When Angion Biomedica Corp. went public?

Angion Biomedica Corp. is publicly traded company for more then 4 years since IPO on 5 Feb 2021.
What is Angion Biomedica Corp.'s official website?

The official website for Angion Biomedica Corp. is angion.com.
Where are Angion Biomedica Corp.'s headquarters?

Angion Biomedica Corp. is headquartered at 51 Charles Lindbergh Boulevard, Uniondale, NY.
How can i contact Angion Biomedica Corp.?

Angion Biomedica Corp.'s mailing address is 51 Charles Lindbergh Boulevard, Uniondale, NY and company can be reached via phone at +41 56554899.

Angion Biomedica Corp.

angion.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primarily in the kidney and lung. It also develops ANG-3777, a hepatocyte growth factor mimetic to treat acute organ injuries, such as delayed graft function; ROCK2 inhibitors programs for fibrotic diseases; and CYP11B2 inhibitor program. The company was incorporated in 1998 and is based in Uniondale, New York.

+41 56554899

51 Charles Lindbergh Boulevard
Uniondale, NY 11553

CIK: 0001601485
ISIN: US03476J1079
CUSIP: 03476J107